Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STEM CELL FACTOR REGULATION AS MEDICAL DEVICES COULD EASE PREMARKET RULES, FDAer SUGGESTS; PHS XENOTRANSPLANTATION GUIDELINES EXPECTED "IMMINENTLY"

This article was originally published in The Gray Sheet

Executive Summary

FDA regulation of stem cell growth factors could be eased by classifying the products as medical devices, Philip Noguchi, director of the Division of Cellular and Gene Therapy in FDA's Center for Biologics Evaluation and Research, said at an International Business Communication meeting in San Francisco Jan. 18.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005345

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel